Grand Pharmaceutical Group Ltd
HKEX:512
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
3.28
5.62
|
Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Grand Pharmaceutical Group Ltd
Cash Paid for Dividends
Grand Pharmaceutical Group Ltd
Cash Paid for Dividends Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Cash Paid for Dividends | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
G
|
Grand Pharmaceutical Group Ltd
HKEX:512
|
Cash Paid for Dividends
-HK$496.9m
|
CAGR 3-Years
11%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
S
|
SSY Group Ltd
HKEX:2005
|
Cash Paid for Dividends
-HK$504.8m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-26%
|
|
U
|
United Laboratories International Holdings Ltd
HKEX:3933
|
Cash Paid for Dividends
-ÂĄ581.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Sino Biopharmaceutical Ltd
HKEX:1177
|
Cash Paid for Dividends
-ÂĄ632.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
C
|
China Resources Pharmaceutical Group Ltd
HKEX:3320
|
Cash Paid for Dividends
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
H
|
HUTCHMED (China) Ltd
HKEX:13
|
Cash Paid for Dividends
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Grand Pharmaceutical Group Ltd
Glance View
Grand Pharmaceutical Group Ltd. engages in the development, manufacture and distribution of pharmaceutical products. The firm is principally engaged in manufacturing and sales of pharmaceutical preparations and medical devices, bio-technology products, nutrition products, specialized pharmaceutical raw materials and other products. The main products of the Company cover the anti-tumor, cardiovascular emergency pharmaceutical products and advanced cerebro-cardiovascular intervention advanced medical devices, anti-virus and anti-infection, respiratory and ear-nose-throat (ENT), bio-health products and specialized pharmaceutical ingredients.
See Also
What is Grand Pharmaceutical Group Ltd's Cash Paid for Dividends?
Cash Paid for Dividends
-496.9m
HKD
Based on the financial report for Jun 30, 2024, Grand Pharmaceutical Group Ltd's Cash Paid for Dividends amounts to -496.9m HKD.
What is Grand Pharmaceutical Group Ltd's Cash Paid for Dividends growth rate?
Cash Paid for Dividends CAGR 5Y
-11%
Over the last year, the Cash Paid for Dividends growth was 0%. The average annual Cash Paid for Dividends growth rates for Grand Pharmaceutical Group Ltd have been 11% over the past three years , -11% over the past five years .